Table 1 Open in new tab Patient...

Characteristics	Biomarker‐selected trial	Conventional chemotherapy	p value
AGC cohort, n = 100
	n = 33	n = 67
Gender
Male	22	40	.514
Female	11	28
Age, years
Median	56.0	56.0	.953
ECOG PS
0–1	32	68	1.000
No. of Metastatic sites
<2	20	51	1.000
2≤	12	32
Line of chemotherapy at the time of genome‐based treatment decision
2	21	59	.032
3≤	11	9
CRC cohort, n = 32
	n = 10	n = 22
Gender
Male	6	15	.703
Female	4	7
Age, years
Median	53.0	58.0	.813
ECOG PS
0–1	9	22	.313
2	1	0
No. of metastatic sites
<2	1	5	.637
2≤	9	17
Line of chemotherapy at the time of genome‐based treatment decision
3	4	9	1.000
4≤	6	13
Pancreas, biliary tract cancer cohort, n = 23
	n = 1	n = 22
Gender
Male	1	15	1.000
Female	0	7
Age, years
Median	61.0	59.0	‐
ECOG PS
0–1	1	22	1.000
No. of metastatic sites
<2	1	13	1.000
2≤	0	9
Line of chemotherapy at the time of genome‐based treatment decision
2	0	20	.130
3≤	1	2
Sarcoma and other cancer cohort, n = 64
	n = 16	n = 48
Gender
Male	10	32	.913
Female	6	16
Age, years
Median	48.0	53.5	.806
ECOG PS
0–1	16	48	1.000
No. of metastatic sites
<2	11	22	.164
≥2	5	26
Line of chemotherapy at the time of genome‐based treatment decision
2	6	13	.758
3≤	10	35

Characteristics

Biomarker‐selected trial

Conventional chemotherapy

p value

AGC cohort, n = 100

n = 33

n = 67

Gender

Male

.514

Female

Age, years

Median

56.0

.953

ECOG PS

0–1

1.000

No. of Metastatic sites

1.000

2≤

Line of chemotherapy at the time of genome‐based treatment decision

.032

3≤

CRC cohort, n = 32

n = 10

n = 22

Gender

Male

.703

Female

Age, years

Median

53.0

58.0

.813

ECOG PS

0–1

.313

No. of metastatic sites

.637

2≤

Line of chemotherapy at the time of genome‐based treatment decision

1.000

4≤

Pancreas, biliary tract cancer cohort, n = 23

n = 1

n = 22

Gender

Male

1.000

Female

Age, years

Median

61.0

59.0

‐

ECOG PS

0–1

1.000

No. of metastatic sites

1.000

2≤

Line of chemotherapy at the time of genome‐based treatment decision

.130

3≤

Sarcoma and other cancer cohort, n = 64

n = 16

n = 48

Gender

Male

.913

Female

Age, years

Median

48.0

53.5

.806

ECOG PS

0–1

1.000

No. of metastatic sites

.164

≥2

Line of chemotherapy at the time of genome‐based treatment decision

.758

3≤

Characteristics	Biomarker‐selected trial	Conventional chemotherapy	p value
AGC cohort, n = 100
	n = 33	n = 67
Gender
Male	22	40	.514
Female	11	28
Age, years
Median	56.0	56.0	.953
ECOG PS
0–1	32	68	1.000
No. of Metastatic sites
<2	20	51	1.000
2≤	12	32
Line of chemotherapy at the time of genome‐based treatment decision
2	21	59	.032
3≤	11	9
CRC cohort, n = 32
	n = 10	n = 22
Gender
Male	6	15	.703
Female	4	7
Age, years
Median	53.0	58.0	.813
ECOG PS
0–1	9	22	.313
2	1	0
No. of metastatic sites
<2	1	5	.637
2≤	9	17
Line of chemotherapy at the time of genome‐based treatment decision
3	4	9	1.000
4≤	6	13
Pancreas, biliary tract cancer cohort, n = 23
	n = 1	n = 22
Gender
Male	1	15	1.000
Female	0	7
Age, years
Median	61.0	59.0	‐
ECOG PS
0–1	1	22	1.000
No. of metastatic sites
<2	1	13	1.000
2≤	0	9
Line of chemotherapy at the time of genome‐based treatment decision
2	0	20	.130
3≤	1	2
Sarcoma and other cancer cohort, n = 64
	n = 16	n = 48
Gender
Male	10	32	.913
Female	6	16
Age, years
Median	48.0	53.5	.806
ECOG PS
0–1	16	48	1.000
No. of metastatic sites
<2	11	22	.164
≥2	5	26
Line of chemotherapy at the time of genome‐based treatment decision
2	6	13	.758
3≤	10	35

Table 1

Open in new tab

Patient characteristics

Characteristics	Biomarker‐selected trial	Conventional chemotherapy	p value
AGC cohort, n = 100
	n = 33	n = 67
Gender
Male	22	40	.514
Female	11	28
Age, years
Median	56.0	56.0	.953
ECOG PS
0–1	32	68	1.000
No. of Metastatic sites
<2	20	51	1.000
2≤	12	32
Line of chemotherapy at the time of genome‐based treatment decision
2	21	59	.032
3≤	11	9
CRC cohort, n = 32
	n = 10	n = 22
Gender
Male	6	15	.703
Female	4	7
Age, years
Median	53.0	58.0	.813
ECOG PS
0–1	9	22	.313
2	1	0
No. of metastatic sites
<2	1	5	.637
2≤	9	17
Line of chemotherapy at the time of genome‐based treatment decision
3	4	9	1.000
4≤	6	13
Pancreas, biliary tract cancer cohort, n = 23
	n = 1	n = 22
Gender
Male	1	15	1.000
Female	0	7
Age, years
Median	61.0	59.0	‐
ECOG PS
0–1	1	22	1.000
No. of metastatic sites
<2	1	13	1.000
2≤	0	9
Line of chemotherapy at the time of genome‐based treatment decision
2	0	20	.130
3≤	1	2
Sarcoma and other cancer cohort, n = 64
	n = 16	n = 48
Gender
Male	10	32	.913
Female	6	16
Age, years
Median	48.0	53.5	.806
ECOG PS
0–1	16	48	1.000
No. of metastatic sites
<2	11	22	.164
≥2	5	26
Line of chemotherapy at the time of genome‐based treatment decision
2	6	13	.758
3≤	10	35

Characteristics	Biomarker‐selected trial	Conventional chemotherapy	p value
AGC cohort, n = 100
	n = 33	n = 67
Gender
Male	22	40	.514
Female	11	28
Age, years
Median	56.0	56.0	.953
ECOG PS
0–1	32	68	1.000
No. of Metastatic sites
<2	20	51	1.000
2≤	12	32
Line of chemotherapy at the time of genome‐based treatment decision
2	21	59	.032
3≤	11	9
CRC cohort, n = 32
	n = 10	n = 22
Gender
Male	6	15	.703
Female	4	7
Age, years
Median	53.0	58.0	.813
ECOG PS
0–1	9	22	.313
2	1	0
No. of metastatic sites
<2	1	5	.637
2≤	9	17
Line of chemotherapy at the time of genome‐based treatment decision
3	4	9	1.000
4≤	6	13
Pancreas, biliary tract cancer cohort, n = 23
	n = 1	n = 22
Gender
Male	1	15	1.000
Female	0	7
Age, years
Median	61.0	59.0	‐
ECOG PS
0–1	1	22	1.000
No. of metastatic sites
<2	1	13	1.000
2≤	0	9
Line of chemotherapy at the time of genome‐based treatment decision
2	0	20	.130
3≤	1	2
Sarcoma and other cancer cohort, n = 64
	n = 16	n = 48
Gender
Male	10	32	.913
Female	6	16
Age, years
Median	48.0	53.5	.806
ECOG PS
0–1	16	48	1.000
No. of metastatic sites
<2	11	22	.164
≥2	5	26
Line of chemotherapy at the time of genome‐based treatment decision
2	6	13	.758
3≤	10	35

Abbreviations: AGC, advanced gastric cancer; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group Performance status.

This Feature Is Available To Subscribers Only